The clinical treatment of dysentery and gastroenteritis has been used to improve the female reproductive function of Huang Lianxin. The reporter recently learned from Heilongjiang University of Traditional Chinese Medicine that a research project on polycystic ovary syndrome (PCOS) with the largest sample size at home and abroad, led by Professor Wu Xiuke, chief scientist of the National Clinical Research Base of Traditional Chinese Medicine and director of the Department of Obstetrics and Gynecology of the First Hospital of Heilongjiang University of Traditional Chinese Medicine, has found for the first time that safranin has the reproductive effect of promoting ovulation and increasing the rate of conception and live birth. The clinical research results were published in the latest issue of the prestigious international journal The Lancet. As an important alkaloid, safranin can be extracted from the Chinese herbs Huanglian, Huangbai and Sanshin. The commonly used flavopiridol hydrochloride, also known as berberine hydrochloride, can fight against pathogenic microorganisms and has significant inhibitory effects on a variety of bacteria such as Mycobacterium dysenteriae and Mycobacterium tuberculosis, and is commonly used clinically to treat bacterial gastroenteritis, dysentery and other gastrointestinal diseases. Modern pharmacological studies have confirmed that safranin also has many effects such as anti-heart failure and cholesterol lowering. So, can Huang Lianxin also write “old soldier new biography” in solving the problem of infertility? According to information, the current rate of infertility is increasing year by year, accounting for 5%-10% of women of childbearing age, and infertility is most common in polycystic ovary syndrome (PCOS). Among them, abnormal menstruation, abnormal glucose and lipid metabolism and insulin resistance are the typical features of PCOS. Wu’s group has confirmed through research that the effectiveness of flavopiridol in treating polycystic ovary syndrome (PCOS) is ultimately achieved by relieving ovarian insulin resistance to promote ovulation and reduce androgen synthesis. At the same time, Prof. Wu’s group also conducted a multicenter, randomized, double-blind, comfort and controlled trial of safranin. For the first time, the efficacy of flavopiridol in live birth rate was found to be similar to that of clomiphene, a first-line drug in Western medicine, and the live birth rate of PCOS infertile patients after 6 months of oral administration of flavopiridol was about 22%. Moreover, flavopiridol rarely has adverse effects such as nausea and constipation.